Advancing the Therapeutic Pipeline in Alport Syndrome

Join the Kidney Health Initiative (KHI) for a mixer focused on the future of Alport syndrome therapies. We’ll share updates from our December 2025 FDA campus meeting, where international partners and regulators came together to advance clinical and surrogate endpoint validation—work that has a significant impact on the entire therapeutic pipeline. This session will highlight the current status of the pharmaceutical pipeline in Alport syndrome, key challenges and opportunities in drug development for this rare genetic kidney disease, and how KHI is partnering with industry at every stage—from preclinical exploration to clinical trial design and patient recruitment. Don’t miss this opportunity to hear the latest insights and connect with others committed to accelerating treatments for the Alport community.